StreetInsider.com News Articles

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Mon, 05 Oct 2026 08:45:00 -0400

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Mon, 05 Oct 2026 08:45:00 -0400

A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease

Immix Biopharma closes $125M stock offering at $11 per share

Wed, 30 Sep 2026 17:15:09 -0400

Immix Biopharma, Inc. (NASDAQ: IMMX) has closed an underwritten registered offering of 11,363,637 shares of common stock at $11.00 per share, according to a company statement.

The net proceeds to the company, after deducting underwriting discounts, commissions, and other offering expenses, totaled approximately $117.1 million. Immix said it intends to use the funds for NXC-201 development, working capital, and general corporate purposes.

J.P. Morgan acted as the sole book-running manager for the offering. The shares were sold pursuant to a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on Jan. 9, 2026, and declared effective on

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Wed, 30 Sep 2026 17:15:00 -0400

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $117.1 million.

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Wed, 30 Sep 2026 17:15:00 -0400

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

Form 8-K Immix Biopharma, Inc. For: Sep 29

Wed, 30 Sep 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260930/27129440.html

Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens on Interim Results for NEXICART-2 Trial

Wed, 30 Sep 2026 04:18:48 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $23.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).

The analyst commented, "We reiterate our Market Outperform rating and price target of $23 for Immix Biopharma based on a revenue and earnings multiple analysis. Yesterday, Immix reported interim results based on all 45 patients treated in the NEXICART-2 trial, showcasing what we believe could be best-in-class results in relapsed/refractory AL amyloidosis. The company concurrently raised $125MM in an underwritten offering from dedicated marquee healthcare investors. Based on the conference call and the capital raised, we remain confident in the BLA submission

Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc.

Tue, 29 Sep 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260929/27117373.html

Form 424B5 Immix Biopharma, Inc.

Tue, 29 Sep 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260929/27117369.html

Immix Biopharma prices $125M common stock offering at $11 per share

Tue, 29 Sep 2026 07:05:13 -0400

Immix Biopharma, Inc. (Nasdaq: IMMX) priced an underwritten registered offering of 11,363,637 shares of common stock at $11.00 per share, according to a press release statement. The offering is expected to generate $125 million in gross proceeds before underwriting discounts, commissions, and other expenses.

The offering is expected to close on or about September 30, 2026, subject to customary closing conditions. The company said it intends to use the net proceeds to fund development of its NXC-201 drug candidate, as well as for working capital and general corporate purposes.

J.P. Morgan is acting as sole book-running manager for the offering. Participating institutional

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Tue, 29 Sep 2026 07:05:00 -0400

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

Immix intends

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Tue, 29 Sep 2026 07:05:00 -0400

Immix intends

Immix Biopharma reports 89% complete response rate in NXC-201 trial

Tue, 29 Sep 2026 07:02:56 -0400

Immix Biopharma, Inc. (Nasdaq: IMMX) announced an interim update from its NEXICART-2 Phase 2 clinical trial showing that its CAR-T therapy candidate NXC-201 produced an 89% complete response rate across all 45 enrolled patients with relapsed/refractory AL Amyloidosis, as assessed by an independent review committee.

According to the company's statement, all 25 newly enrolled patients are either in complete response or minimum residual disease (MRD)-negative, with 21 of 25 achieving complete response and the remaining 4 already MRD-negative. The company noted that, to date, all patients who achieved MRD-negativity subsequently reached complete response within one year of treatment.

In the four patients

Immix Biopharma reports 89% complete response rate in NXC-201 trial

Tue, 29 Sep 2026 07:02:56 -0400

In the four patients

Immix Biopharma reports 89% complete response rate in NXC-201 trial

Tue, 29 Sep 2026 07:02:56 -0400

In the four patients

Form 8-K Immix Biopharma, Inc. For: Sep 29

Tue, 29 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27117196.html

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po

Tue, 29 Sep 2026 07:00:00 -0400

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –

– Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee –

– In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) –

– No relapses observed for any patient who reached

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po

Tue, 29 Sep 2026 07:00:00 -0400

– 100% (25/25) of new patients are either in complete response (CR) or MRD-negative (21/25 are in CR; remaining 4/25 are MRD-negative) –

– To-date, all patients achieving MRD-negativity reached CR within one year of treatment –

– Across all forty-five patients, NXC-201 produced an 89% (40/45) CR rate as assessed by independent review committee –

– In four pending patients that are already MRD-negative, MRD-negativity in bone marrow predicts future CR, potentially increasing future CR rate up to 98% (44/45) –

– No relapses observed for any patient who reached

Immix Biopharma, Inc. (IMMX) PT Raised to $26 at Mizuho

Tue, 15 Sep 2026 07:57:08 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $26.00 (from $15.00) while maintaining a Outperform rating.
The analyst comments "Ahead of next P2 NEXICART-2 study data for NXC-201 in R/R AL amyloidosis (a rare disease of abnormal amyloid buildup in the body), we raise our PT on IMMX to $26 (vs. $15 prior). Having already projected peak NXC-201 global revenue in R/R amyloidosis at ~$1bn, we now model a second potential indication for NXC-201, the first-line/1L AL amyloidosis setting, for which (1) a P3 study is planned in 1H27, and (2) we see as

Immix Biopharma, Inc. (IMMX) PT Raised to $26 at Mizuho

Tue, 15 Sep 2026 07:57:08 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $26.00 (from $15.00) while maintaining a Outperform rating.
The analyst comments "Ahead of next P2 NEXICART-2 study data for NXC-201 in R/R AL amyloidosis (a rare disease of abnormal amyloid buildup in the body), we raise our PT on IMMX to $26 (vs. $15 prior). Having already projected peak NXC-201 global revenue in R/R amyloidosis at ~$1bn, we now model a second potential indication for NXC-201, the first-line/1L AL amyloidosis setting, for which (1) a P3 study is planned in 1H27, and (2) we see as

Immix Biopharma, Inc. (IMMX) PT Raised to $26 at Mizuho

Tue, 15 Sep 2026 07:57:08 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Immix Biopharma, Inc. (NASDAQ: IMMX) to $26.00 (from $15.00) while maintaining a Outperform rating.
The analyst comments "Ahead of next P2 NEXICART-2 study data for NXC-201 in R/R AL amyloidosis (a rare disease of abnormal amyloid buildup in the body), we raise our PT on IMMX to $26 (vs. $15 prior). Having already projected peak NXC-201 global revenue in R/R amyloidosis at ~$1bn, we now model a second potential indication for NXC-201, the first-line/1L AL amyloidosis setting, for which (1) a P3 study is planned in 1H27, and (2) we see as

Form SCHEDULE 13G Immix Biopharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:36:00 -0400
si-local-file:///var/storage/secattach/20260814/26927299.html

Form SCHEDULE 13G Immix Biopharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC

Fri, 14 Aug 2026 11:36:00 -0400
si-local-file:///var/storage/secattach/20260814/26927299.html

Immix Biopharma (IMMX) Reiterated at Market Outperform by Citizens on Upcoming Milestones

Fri, 14 Aug 2026 04:32:48 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $23.00 price target on Immix Biopharma, Inc. (NASDAQ: IMMX).
The analyst commented, "We reiterate our Market Outperform rating and price target of $23 for Immix Biopharma based on a revenue and earnings multiples analysis. Recently, Immix reported 2Q26 earnings, and based on our conversation with management, we remain confident in regard to the cadence of value-driving milestones over the next 6-12 months. With NXC-201 on track to report top-line results in September and file a BLA in 1H27, a potential commercial launch by year-end 2026/early 2027, and a solid cash position

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:47:00 -0400
si-local-file:///var/storage/secattach/20260813/26919254.html